OncoMatch/Clinical Trials/NCT06518434
A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
Is NCT06518434 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Medical Cannabis for hepatocellular carcinoma.
Treatment: Medical Cannabis — to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable HCC patients based on mRECIST and RECIST criteria
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: systemic treatment
Previous systemic treatment for HCC
Lab requirements
Liver function
Non-cirrhosis or Child Pugh A cirrhosis; Child Pugh B or C cirrhosis [excluded]
Cardiac function
No myocardial infarction or clinically significant cardiac dysfunction within the last 12 months; no cardiac disorder that would put participant at risk of clinically significant arrhythmia or myocardial infarction
Non-cirrhosis or Child Pugh A cirrhosis; Child Pugh B or C cirrhosis [excluded]; Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06518434 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages